×
News Home

Is Cingulate Inc (CING) Stock About to Get Hot Thursday?

Thursday, August 18, 2022 11:51 AM | InvestorsObserver Analysts
Is Cingulate Inc (CING) Stock About to Get Hot Thursday?

Overall market sentiment has been down on Cingulate Inc (CING) stock lately. CING receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Cingulate Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CING!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CING Stock Today?

Cingulate Inc (CING) stock is trading at $1.45 as of 11:50 AM on Thursday, Aug 18, an increase of $0.08, or 5.84% from the previous closing price of $1.37. The stock has traded between $1.41 and $1.50 so far today. Volume today is low. So far 47,697 shares have traded compared to average volume of 78,840 shares.

More About Cingulate Inc

Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. Click Here to get the full Stock Report for Cingulate Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App